NCT06678230View on ClinicalTrials.gov

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

October 20, 2025

Conditions
Breast Cancer
Interventions
DRUG

Anlotinib

Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.

Trial Locations (1)

130021

Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT06678230 - Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter